Andra AP fonden Buys 11,300 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Andra AP fonden boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the medical research company’s stock after acquiring an additional 11,300 shares during the quarter. Andra AP fonden’s holdings in IQVIA were worth $12,380,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Edgestream Partners L.P. bought a new stake in IQVIA during the fourth quarter worth approximately $6,465,000. Ashton Thomas Private Wealth LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $262,000. Callan Family Office LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $355,000. Carmel Capital Partners LLC grew its stake in shares of IQVIA by 50.8% during the fourth quarter. Carmel Capital Partners LLC now owns 11,396 shares of the medical research company’s stock valued at $2,239,000 after buying an additional 3,838 shares during the last quarter. Finally, Inceptionr LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $513,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $191.69 on Friday. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.73. The stock has a fifty day moving average price of $197.79 and a 200-day moving average price of $213.11. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $33.80 billion, a PE ratio of 25.56, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup cut their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Stephens started coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Finally, BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.